Does chronic inflammation disrupt liver and muscle insulin signaling and force higher insulin output?

Chronic metabolic inflammation is a key driver of systemic insulin resistance, particularly through the disruption of metabolic signaling in the liver and skeletal muscle. This process creates a feedback loop that forces the pancreas to increase insulin production to maintain glucose control.

Mechanistic explanations

Inflammation impairs insulin sensitivity by activating specific inhibitory pathways that block the insulin receptor's signal.

• Cytokine Interference: Pro-inflammatory mediators, including Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6), activate inhibitory kinases such as c-Jun N-terminal kinase (JNK) and p38 MAP kinase.
• Signaling Blockade: These kinases cause inhibitory phosphorylation of Insulin Receptor Substrates (IRS-1 and IRS-2). This prevents the activation of downstream molecules like AKT, which are essential for glucose transport and metabolic regulation in the liver and skeletal muscle.
• Tissue Impact: In the liver, inflammatory metabolites and markers like ferritin trigger endoplasmic reticulum stress, further downregulating IRS expression. In skeletal muscle, these processes directly impair the recruitment of glucose transporters to the cell surface.

Clinical evidence and implications

The body attempts to overcome this signaling blockade through a process known as compensatory hyperinsulinemia.

• Compensatory Response: As peripheral tissues become less responsive due to inflammatory signaling, pancreatic beta-cells increase their insulin output to keep blood glucose levels within a normal range.
• Pathogenesis: Studies in high-risk populations confirm that peripheral insulin resistance and elevated fasting insulin levels precede the development of type 2 diabetes.
• Exhaustion Phase: This increased demand is sustainable only until a threshold of beta-cell exhaustion is reached. When the pancreas can no longer produce enough insulin to overcome the resistance, blood glucose levels rise, leading to clinical hyperglycemia.

Bottom line

Inflammation directly disrupts insulin signaling in the liver and muscle via inhibitory phosphorylation of key proteins. This resistance necessitates higher insulin output (hyperinsulinemia) to maintain glucose balance, a compensatory state that eventually contributes to pancreatic strain and metabolic decline.